Modulation of P-glycoprotein-mediated anticancer drug accumulation, cytotoxicity, and ATPase activity by flavonoid

Van H Tran1, Denese Marks, Rujee K Duke

  • 1Faculty of Pharmacy, The University of Sydney, New South Wales, Australia.

Nutrition and Cancer
|April 5, 2011
PubMed

Insights

Flavonoids can alter how cancer drugs like daunorubicin and vinblastine work in resistant cells. Some flavonoids decrease daunorubicin accumulation and toxicity, while others increase vinblastine accumulation and toxicity.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Cancer Biology

Background:

  • Flavonoids are plant compounds found in foods and herbal medicines.
  • Many cancer patients use herbal medicines alongside chemotherapy.
  • P-glycoprotein (P-gp) is an ABC transporter that confers multidrug resistance in cancer cells.

Purpose of the Study:

  • To investigate how flavonoids affect the accumulation and cytotoxicity of P-gp substrate anticancer drugs.
  • To understand the interaction between flavonoids and P-gp activity.

Main Methods:

  • Tested 30 flavonoids on vinblastine-resistant T-cell leukemia (CEM/VBL(100)) overexpressing P-gp.
  • Assessed the effects of flavonoids on the accumulation and cytotoxicity of vinblastine (VLB), daunorubicin (DNR), and colchicine (COL).
  • Measured P-gp ATPase activity in the presence of flavonoids and P-gp substrates.

Main Results:

  • Most flavonoids decreased DNR accumulation and cytotoxicity in resistant cells.
  • Some flavonoids enhanced VLB accumulation and cytotoxicity.
  • Flavonoids had no effect on COL accumulation or cytotoxicity.
  • Effects on drug accumulation and cytotoxicity correlated with flavonoid modulation of P-gp ATPase activity.

Conclusions:

  • Flavonoids can have differential effects on anticancer drug accumulation and efficacy, depending on the drug and flavonoid structure.
  • These findings highlight the potential for drug-herb interactions in cancer therapy.
  • Consideration of flavonoid interactions is crucial for designing effective combination cancer treatments.

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...